{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T23:56:22Z","timestamp":1765151782064},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Indian Council of Medical Research (ICMR), New Delhi, India","award":["VIR\/28\/2010-ECD-I","3\/1\/3JRF-2008\/MPD"],"award-info":[{"award-number":["VIR\/28\/2010-ECD-I","3\/1\/3JRF-2008\/MPD"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.gene.2015.04.060","type":"journal-article","created":{"date-parts":[[2015,4,26]],"date-time":"2015-04-26T02:40:37Z","timestamp":1430016037000},"page":"22-30","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Response to potent anti-HBV agents in chronic hepatitis B and combined effect of HBV reverse transcriptase mutations"],"prefix":"10.1016","volume":"567","author":[{"given":"Bhupesh","family":"Singla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajasri","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuradha","family":"Chakraborti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bal Krishan","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shweta","family":"Kapil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogesh K.","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil K.","family":"Arora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashim","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radha K.","family":"Dhiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Duseja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gene.2015.04.060_bb0005","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1128\/AAC.02600-12","article-title":"Efficacy of tenofovir in patients with lamivudine failure is not different from that in nucleoside\/nucleotide analogue-naive patients with chronic hepatitis B","volume":"57","author":"Baran","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl.","key":"10.1016\/j.gene.2015.04.060_bb0010","first-page":"409A","article-title":"A viral load reduction >3 log at 12week of entecavir treatment correlated with HBe seroconversion in HBeag positive patients. Results from a real-life setting study (the ORIENTE study)","volume":"52","author":"Buti","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.gene.2015.04.060_bb0015","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2015.04.060_bb0020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.gene.2015.04.060_bb0025","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.cld.2007.08.005","article-title":"Long-term outcomes in hepatitis B: the REVEAL-HBV study","volume":"11","author":"Chen","year":"2007","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.gene.2015.04.060_bb0030","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/hep.21422","article-title":"Resistance after two years of entecavir treatment in nucleoside-naive patients is rare","volume":"44","author":"Colonno","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.gene.2015.04.060_bb0035","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1128\/AAC.00138-06","article-title":"Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus","volume":"50","author":"Delaney","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.gene.2015.04.060_bb0040","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00044011-200727010-00003","article-title":"Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients","volume":"27","author":"Dienstag","year":"2007","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.gene.2015.04.060_bb0045","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1002\/jmv.20605","article-title":"Hepatitis B virus genetic diversity","volume":"78","author":"Echevarr\u00eda","year":"2006","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.gene.2015.04.060_bb0050","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B","volume":"50","author":"European Association for the Study of the Liver","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.gene.2015.04.060_bb0055","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00239-001-0084-z","article-title":"A revised evolutionary history of hepatitis B virus (HBV)","volume":"54","author":"Fares","year":"2002","journal-title":"J. Mol. Evol."},{"key":"10.1016\/j.gene.2015.04.060_bb0060","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1101\/gr.9.9.868","article-title":"CAP3: A DNA sequence assembly program","volume":"9","author":"Huang","year":"1999","journal-title":"Genome Res."},{"key":"10.1016\/j.gene.2015.04.060_bb0065","first-page":"338","article-title":"AASLD updates chronic hepatitis B recommendations","volume":"79","author":"Huntzinger","year":"2009","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.gene.2015.04.060_bb0070","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gene.2015.04.060_bb0075","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.cgh.2007.06.015","article-title":"Risk and predictors of mortality associated with chronic hepatitis B infection","volume":"5","author":"Iloeje","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.gene.2015.04.060_bb0080","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000323521","article-title":"Antiviral resistance mutations and genotype-associated amino acid substitutions in treatment-na\u00efve hepatitis B virus-infected individuals from the Indian subcontinent","volume":"55","author":"Ismail","year":"2012","journal-title":"Intervirology"},{"key":"10.1016\/j.gene.2015.04.060_bb0085","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4103\/0974-2727.98664","article-title":"Laboratory evaluation of three regimens of treatment of chronic hepatitis B: tenofovir, entecavir and combination of lamivudine and adefovir","volume":"4","author":"Jayakumar","year":"2012","journal-title":"J. Lab. Physicians."},{"key":"10.1016\/j.gene.2015.04.060_bb0090","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/jvh.12144","article-title":"Antiviral efficacy of entecavir in nucleos(t)ide-na\u00efve patients of Black\/African descent with chronic hepatitis B","volume":"21","author":"Jeffers","year":"2014","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.gene.2015.04.060_bb0095","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/hep.26686","article-title":"No detectable resistance to tenofovir disoproxil fumarate after 6years of therapy in patients with chronic hepatitis B","volume":"59","author":"Kitrinos","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.gene.2015.04.060_bb0100","first-page":"19","article-title":"Hepatitis B virus genotype A is more often associated with severe liver disease in northern India than is genotype D","volume":"24","author":"Kumar","year":"2005","journal-title":"Indian J. Gastroenterol."},{"key":"10.1016\/j.gene.2015.04.060_bb0105","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.gastro.2012.05.037","article-title":"Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-na\u00efve patients with chronic hepatitis B","volume":"143","author":"Lok","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gene.2015.04.060_bb0110","doi-asserted-by":"crossref","first-page":"e39028","DOI":"10.1371\/journal.pone.0039028","article-title":"Hepatitis B virus gene mutations in liver diseases: a report from New Delhi","volume":"7","author":"Malik","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.gene.2015.04.060_bb0115","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2015.04.060_bb0120","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/hep.25818","article-title":"Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B","volume":"56","author":"Murray","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.gene.2015.04.060_bb0125","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1743-422X-10-56","article-title":"Characterization of antiviral resistance mutations among the Eastern Indian Hepatitis B virus infected population","volume":"10","author":"Panigrahi","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/j.gene.2015.04.060_bb0130","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3748\/wjg.15.753","article-title":"Hepatitis B virus mutations potentially conferring adefovir\/tenofovir resistance in treatment-naive patients","volume":"15","author":"Pastor","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.gene.2015.04.060_bb0135","first-page":"314","article-title":"An open label prospective observational study to evaluate the efficacy of entecavir in HBeAg positive treatment na\u00efve chronic hepatitis B patients in a tertiary care center in eastern India","volume":"32","author":"Patra","year":"2011","journal-title":"Trop. Gastroenterol."},{"key":"10.1016\/j.gene.2015.04.060_bb0140","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/jvh.12013","article-title":"Dynamics of hepatitis B virus quasispecies heterogeneity and virologic response in patients receiving low-to-moderate genetic barrier nucleoside analogs","volume":"20","author":"Peveling-Oberhag","year":"2013","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.gene.2015.04.060_bb0145","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/135965350901400504","article-title":"Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients","volume":"14","author":"Pollicino","year":"2009","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.gene.2015.04.060_bb0150","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12664-013-0395-1","article-title":"Serum HBsAg quantification in treatment-na\u00efve Indian patients with chronic hepatitis B","volume":"33","author":"Ramachandran","year":"2014","journal-title":"Indian J. Gastroenterol."},{"key":"10.1016\/j.gene.2015.04.060_bb0155","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2008.10.033","article-title":"Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy","volume":"50","author":"Reijnders","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.gene.2015.04.060_bb0160","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nprot.2010.5","article-title":"I-TASSER: a unified platform for automated protein structure and function prediction","volume":"5","author":"Roy","year":"2010","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.gene.2015.04.060_bb0165","doi-asserted-by":"crossref","first-page":"846849","DOI":"10.1155\/2013\/846849","article-title":"Emergence of hepatitis B virus genotype F in Aligarh region of north India","volume":"2013","author":"Sami","year":"2013","journal-title":"Adv. Virol."},{"key":"10.1016\/j.gene.2015.04.060_bb0170","series-title":"Fields Virology","first-page":"2977","article-title":"Hepadnaviruses","author":"Seeger","year":"2007"},{"key":"10.1016\/j.gene.2015.04.060_bb0175","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2006.01.001","article-title":"HBV drug resistance: mechanisms, detection and interpretation","volume":"44","author":"Shaw","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.gene.2015.04.060_bb0180","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/135965350501000612","article-title":"Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir","volume":"10","author":"Sheldon","year":"2005","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.gene.2015.04.060_bb0185","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/jmv.23608","article-title":"Hepatitis B virus reverse transcriptase mutations in treatment na\u00efve chronic hepatitis B patients","volume":"85","author":"Singla","year":"2013","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.gene.2015.04.060_bb0190","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1007\/s11033-014-3339-7","article-title":"Levels of hepatitis B virus replicative intermediate in serum samples of chronic hepatitis B patients","volume":"41","author":"Singla","year":"2014","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.gene.2015.04.060_bb0195","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jcv.2007.03.004","article-title":"Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H","volume":"39","author":"Suzuki","year":"2007","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.gene.2015.04.060_bb0200","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2008.07.038","article-title":"The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes","volume":"50","author":"Svicher","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.gene.2015.04.060_bb0205","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.48.9.3498-3507.2004","article-title":"Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine","volume":"48","author":"Tenney","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.gene.2015.04.060_bb0210","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5years of therapy","volume":"49","author":"Tenny","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.gene.2015.04.060_bb0215","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.23246","article-title":"Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside\/nucleotide analogues","volume":"51","author":"van Bommel","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.gene.2015.04.060_bb0220","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1086\/383144","article-title":"Distribution of hepatitis B virus genotypes in blood donors and chronically infected patients in a tertiary care hospital in southern India","volume":"38","author":"Vivekanandan","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.gene.2015.04.060_bb0225","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.cgh.2013.11.036","article-title":"Mutations in HBV DNA polymerase associated with nucleos(t)ide resistance are rare in treatment-na\u00efve patients","volume":"12","author":"Vutien","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.gene.2015.04.060_bb0230","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/0140-6736(93)92250-W","article-title":"Clinical aspects of hepatitis B virus infection","volume":"342","author":"Wright","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.gene.2015.04.060_bb0235","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-2105-9-40","article-title":"I-TASSER server for protein 3D structure prediction","volume":"9","author":"Zhang","year":"2008","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.gene.2015.04.060_bb0240","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111915004874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111915004874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T03:08:57Z","timestamp":1651806537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111915004874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0378111915004874"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2015.04.060","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to potent anti-HBV agents in chronic hepatitis B and combined effect of HBV reverse transcriptase mutations","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2015.04.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}